QQQ   360.93 (-2.54%)
AAPL   142.40 (-2.04%)
MSFT   285.95 (-2.79%)
FB   342.01 (-3.27%)
GOOGL   2,725.31 (-3.41%)
TSLA   771.57 (-2.50%)
AMZN   3,313.94 (-2.70%)
NVDA   208.25 (-3.86%)
BABA   151.63 (+0.97%)
NIO   35.08 (-4.60%)
CGC   14.22 (-3.33%)
GE   105.85 (+0.47%)
MU   73.92 (-1.68%)
AMD   102.43 (-5.30%)
T   27.23 (-0.62%)
F   14.35 (+1.34%)
ACB   6.77 (+5.95%)
DIS   175.09 (-1.78%)
PFE   42.99 (-1.33%)
BA   218.63 (-2.47%)
AMC   37.61 (-4.30%)
QQQ   360.93 (-2.54%)
AAPL   142.40 (-2.04%)
MSFT   285.95 (-2.79%)
FB   342.01 (-3.27%)
GOOGL   2,725.31 (-3.41%)
TSLA   771.57 (-2.50%)
AMZN   3,313.94 (-2.70%)
NVDA   208.25 (-3.86%)
BABA   151.63 (+0.97%)
NIO   35.08 (-4.60%)
CGC   14.22 (-3.33%)
GE   105.85 (+0.47%)
MU   73.92 (-1.68%)
AMD   102.43 (-5.30%)
T   27.23 (-0.62%)
F   14.35 (+1.34%)
ACB   6.77 (+5.95%)
DIS   175.09 (-1.78%)
PFE   42.99 (-1.33%)
BA   218.63 (-2.47%)
AMC   37.61 (-4.30%)
QQQ   360.93 (-2.54%)
AAPL   142.40 (-2.04%)
MSFT   285.95 (-2.79%)
FB   342.01 (-3.27%)
GOOGL   2,725.31 (-3.41%)
TSLA   771.57 (-2.50%)
AMZN   3,313.94 (-2.70%)
NVDA   208.25 (-3.86%)
BABA   151.63 (+0.97%)
NIO   35.08 (-4.60%)
CGC   14.22 (-3.33%)
GE   105.85 (+0.47%)
MU   73.92 (-1.68%)
AMD   102.43 (-5.30%)
T   27.23 (-0.62%)
F   14.35 (+1.34%)
ACB   6.77 (+5.95%)
DIS   175.09 (-1.78%)
PFE   42.99 (-1.33%)
BA   218.63 (-2.47%)
AMC   37.61 (-4.30%)
QQQ   360.93 (-2.54%)
AAPL   142.40 (-2.04%)
MSFT   285.95 (-2.79%)
FB   342.01 (-3.27%)
GOOGL   2,725.31 (-3.41%)
TSLA   771.57 (-2.50%)
AMZN   3,313.94 (-2.70%)
NVDA   208.25 (-3.86%)
BABA   151.63 (+0.97%)
NIO   35.08 (-4.60%)
CGC   14.22 (-3.33%)
GE   105.85 (+0.47%)
MU   73.92 (-1.68%)
AMD   102.43 (-5.30%)
T   27.23 (-0.62%)
F   14.35 (+1.34%)
ACB   6.77 (+5.95%)
DIS   175.09 (-1.78%)
PFE   42.99 (-1.33%)
BA   218.63 (-2.47%)
AMC   37.61 (-4.30%)
NASDAQ:AXNX

Axonics Stock Forecast, Price & News

$64.73
-2.60 (-3.86 %)
(As of 09/28/2021 02:37 PM ET)
Add
Compare
Today's Range
$63.52
$67.71
50-Day Range
$61.18
$78.66
52-Week Range
$41.13
$79.81
Volume18,703 shs
Average Volume546,618 shs
Market Capitalization$2.99 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.08
30 days | 90 days | 365 days | Advanced Chart
Receive AXNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.


Axonics logo

About Axonics

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women. The company was founded by Raymond W. Cohen, Guang Qiang Jiang, and Danny L. Dearen in March 2012 and is headquartered in Irvine, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXNX
CIK
N/A
Employees
416
Year Founded
N/A

Sales & Book Value

Annual Sales
$111.54 million
Book Value
$7.22 per share

Profitability

Net Income
$-54,920,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$2.99 billion
Next Earnings Date
11/3/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.08 out of 5 stars

Medical Sector

473rd out of 1,353 stocks

Surgical & Medical Instruments Industry

47th out of 123 stocks

Analyst Opinion: 2.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Axonics (NASDAQ:AXNX) Frequently Asked Questions

Is Axonics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Axonics stock.
View analyst ratings for Axonics
or view top-rated stocks.

What stocks does MarketBeat like better than Axonics?

Wall Street analysts have given Axonics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Axonics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Axonics' next earnings date?

Axonics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Axonics
.

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) announced its earnings results on Wednesday, August, 4th. The company reported ($0.59) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.10. The business earned $45.87 million during the quarter, compared to analyst estimates of $39.24 million. Axonics had a negative net margin of 45.36% and a negative trailing twelve-month return on equity of 18.01%.
View Axonics' earnings history
.

How has Axonics' stock price been impacted by COVID-19?

Axonics' stock was trading at $30.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AXNX stock has increased by 114.5% and is now trading at $64.83.
View which stocks have been most impacted by COVID-19
.

What guidance has Axonics issued on next quarter's earnings?

Axonics issued an update on its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $186 million-$188 million, compared to the consensus revenue estimate of $178.80 million.

What price target have analysts set for AXNX?

7 brokerages have issued 1 year price objectives for Axonics' shares. Their forecasts range from $57.00 to $79.00. On average, they expect Axonics' share price to reach $69.56 in the next year. This suggests a possible upside of 7.3% from the stock's current price.
View analysts' price targets for Axonics
or view top-rated stocks among Wall Street analysts.

Who are Axonics' key executives?

Axonics' management team includes the following people:

What is Raymond W. Cohen's approval rating as Axonics' CEO?

12 employees have rated Axonics CEO Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among Axonics' employees.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include Raytheon Technologies (RTX), Honeywell International (HON), (OAS), Pfizer (PFE), The Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics IPO?

(AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

What is Axonics' stock symbol?

Axonics trades on the NASDAQ under the ticker symbol "AXNX."

Who are Axonics' major shareholders?

Axonics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (12.67%), BlackRock Inc. (7.12%), Credit Suisse AG (5.65%), Lord Abbett & CO. LLC (4.85%), RTW Investments LP (4.21%) and Vanguard Group Inc. (3.97%). Company insiders that own Axonics stock include Alfred J Ford Jr, Alfred J Ford, Jr, Andera Partners, Bakker Juliet Tammenoms, Danny L Dearen, John Woock, Raphael Wisniewski, Raymond W Cohen, Raymond W Cohen, Rinda Sama and Robert E Mcnamara.
View institutional ownership trends for Axonics
.

Which major investors are selling Axonics stock?

AXNX stock was sold by a variety of institutional investors in the last quarter, including Ziegler Capital Management LLC, Bank of America Corp DE, C WorldWide Group Holding A S, Balyasny Asset Management LLC, JPMorgan Chase & Co., Goldman Sachs Group Inc., Federated Hermes Inc., and Invesco Ltd.. Company insiders that have sold Axonics company stock in the last year include Alfred J Ford Jr, Danny L Dearen, John Woock, Raymond W Cohen, Rinda Sama, and Robert E Mcnamara.
View insider buying and selling activity for Axonics
or view top insider-selling stocks.

Which major investors are buying Axonics stock?

AXNX stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Macquarie Group Ltd., Millennium Management LLC, BlackRock Inc., Frontier Capital Management Co. LLC, Amundi, Vanguard Group Inc., and Dimensional Fund Advisors LP.
View insider buying and selling activity for Axonics
or or view top insider-buying stocks.

How do I buy shares of Axonics?

Shares of AXNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axonics' stock price today?

One share of AXNX stock can currently be purchased for approximately $64.83.

How much money does Axonics make?

Axonics has a market capitalization of $2.99 billion and generates $111.54 million in revenue each year. The company earns $-54,920,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis.

How many employees does Axonics have?

Axonics employs 416 workers across the globe.

What is Axonics' official website?

The official website for Axonics is www.axonics.com.

Where are Axonics' headquarters?

Axonics is headquartered at 26 TECHNOLOGY DRIVE, IRVINE CA, 92618.

How can I contact Axonics?

Axonics' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company can be reached via phone at (866) 722-5738 or via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.